Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 440-443

  Ganti, Apar Kishor ^a,b   Kessinger, Anne ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Chemotherapy; GDC 0449; Hedgehog pathway; Metastatic basal cell carcinoma; Targeted therapy

Indexed keywords

BLEOMYCIN; CHROMOMYCIN A3; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINCRISTINE; ZOLEDRONIC ACID;

BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG TARGETING; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NEEDLE BIOPSY; REVIEW;

AGED; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79961002707     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.12.002     Document Type: Review

References (47)

1. Ramsey ML, Sewell LD. Basal cell carcinoma E-medicine ; 2009. http://emedicine.medscape.com/article/1100003-overview.
2. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001, 63:8-18.
3. Lear J.T., Tan B.B., Smith A.G., Bowers W., Jones P.W., Heagerty A.H., et al. Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med 1997, 90:371-374.
4. Wong C.S., Strange R.C., Lear J.T. Basal cell carcinoma. BMJ 2003, 327:794-798.
5. Thissen M.R., Neumann M.H., Schouten L.J. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999, 135:1177-1183.
6. Jacob A. Observations respecting an ulcer of peculiar characteristics which attacks the lids and other parts of the face. Dublin Hospital Rep 1827, 4:232-239.
7. Beadles D.F. Rodent ulcer. Trans Pathol Soc (Lond) 1894, 45:181.
8. Cunneen T.S., Yong J.L., Benger R. Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Exp Ophthalmol 2008, 36:475-477.
9. Paver K., Poyzer K., Burry N., Deakin M. Letter: the incidence of basal cell carcinoma and their metastases in Australia and New Zealand. Australas J Dermatol 1973, 14:53.
10. Cade S. Malignant disease and its treatment by radium. Williams and Wilkins Company; 1940.
11. Cotran R.S. Metastasizing basal cell carcinomas. Cancer 1961, 14:1036-1040.
12. Lakshmipathi T., Hunt K.M. Metastasizing basal-cell carcinoma. Br J Dermatol 1967, 79:267-270.
13. Scanlon E.F., Volkmer D.D., Oviedo M.A., Khandekar J.D., Victor T.A. Metastatic basal cell carcinoma. J Surg Oncol 1980, 15:171-180.
14. Wronkowski Z. Metastases in dermal basal cell carcinoma. Nowotwory 1968, 18:51-55.
15. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J 2006;12:7.
16. von Domarus H., Stevens P.J. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984, 10:1043-1060.
17. Lo J.S., Snow S.N., Reizner G.T., Mohs F.E., Larson P.O., Hruza G.J. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991, 24:715-719.
18. Snow S.N., Sahl W., Lo J.S., Mohs F.E., Warner T., Dekkinga J.A., et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994, 73:328-335.
19. Berlin J.M., Warner M.R., Bailin P.L. Metastatic basal cell carcinoma presenting as unilateral axillary lymphadenopathy: report of a case and review of the literature. Dermatol Surg 2002, 28:1082-1084.
20. Sitz K.V., Keppen M., Johnson D.F. Metastatic basal cell carcinoma in acquired immunodeficiency syndrome-related complex. JAMA 1987, 257:340-343.
21. Walling H.W., Fosko S.W., Geraminejad P.A., Whitaker D.C., Arpey C.J. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004, 23:389-402.
22. Mikhail G.R., Nims L.P., Kelly A.P., Ditmars D.M., Eyler W.R. Metastatic basal cell carcinoma: review, pathogenesis, and report of two cases. Arch Dermatol 1977, 113:1261-1269.
23. Wermuth B.M., Fajardo L.F. Metastatic basal cell carcinoma. A review. Arch Pathol 1970, 90:458-462.
24. Pickren J.W., Katz A.D. Aspiration metastases from basal cell carcinoma. Cancer 1958, 11:783-789.
25. Christian M.M., Murphy C.M., Wagner R.F. Metastatic basal cell carcinoma presenting as unilateral lymphedema. Dermatol Surg 1998, 24:1151-1153.
26. Woods R.L., Stewart J.F. Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgrad Med J 1980, 56:272-273.
27. Salem P., Hall S.W., Benjamin R.S., Murphy W.K., Wharton J.T., Bodey G.P. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. Cancer Treat Rep 1978, 62:1553-1555.
28. Wieman T.J., Shively E.H., Woodcock T.M. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer 1983, 52:1583-1585.
29. Guthrie T.H., McElveen L.J., Porubsky E.S., Harmon J.D. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985, 55:1629-1632.
30. Guthrie T.H., Porubsky E.S., Luxenberg M.N., Shah K.J., Wurtz K.L., Watson P.R. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990, 8:342-346.
31. Moeholt K., Aagaard H., Pfeiffer P., Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma - a review of the literature. Acta Oncol 1996, 35:677-682.
32. Jefford M., Kiffer J.D., Somers G., Daniel F.J., Davis I.D. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg 2004, 74:704-705.
33. Krahn G., Leiter U., Kaskel P., Udart M., Utikal J., Bezold G., et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001, 37:251-259.
34. Muller H., Eisendle K., Gastl G., Hopfl R., Zelger B. Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab. Br J Dermatol 2008, 158:1386-1388.
35. Caron J., Dereure O., Kerob D., Lebbe C., Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol 2009, 161:702-703.
36. Caro I., Low J.A. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010, 16:3335-3339.
37. Mimeault M., Batra S.K., Sibley D. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010, 62:497-524.
38. Pathi S., Pagan-Westphal S., Baker D.P., Garber E.A., Rayhorn P., Bumcrot D., et al. Comparative biological responses to human Sonic, Indian, and Desert hedgehog. Mech Dev 2001, 106:107-117.
39. Epstein E.H. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008, 8:743-754.
40. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
41. Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272:1668-1671.
42. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
43. Rubin L.L., de Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006, 5:1026-1033.
44. Williams J.A. Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Perspect 2003, 16:657-662.
45. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361:1164-1172.
46. Rudin CM, Weiss GJ, Chang A, Gettinger S, Miller JWH, Eigl B, et al. IPI-926, an inhibitor of the hedgehog pathway, in patients with advanced or metastatic solid tumors. Ann Oncol 2010;21:viii164.
47. Ahnert JR, Baselga J, Tawbi H, Shou Y, Dummer R, Feng W. LDE225, a smoothened (SMO) antagonist: phase I safety and pharmacologic results in patients with advanced tumours. Ann Oncol 2010;21:viii164.